Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 38.68
- Piotroski Score 3.00
- Grade Outperform
- Symbol (PHVS)
- Company Pharvaris N.V.
- Price $20.45
- Changes Percentage (-0.27%)
- Change -$0.06
- Day Low $20.30
- Day High $20.96
- Year High $33.00
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 04/09/2025
- Fiscal Year End N/A
- Average Stock Price Target $42.00
- High Stock Price Target $50.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.70
- Trailing P/E Ratio -5.8
- Forward P/E Ratio -5.8
- P/E Growth -5.8
- Net Income $-100,875,000
